Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TSVT

2seventy bio Inc

Dec 08 • 04:00PM ET

3.10

Dollar change +0.45
Percentage change 16.98	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.91	Insider Own	7.04%	Shs Outstand	50.62M	Perf Week	59.79%
Market Cap	156.92M	Forward P/E	-	EPS next Y	-2.27	Insider Trans	48.34%	Shs Float	47.05M	Perf Month	29.71%
Income	-183.89M	PEG	-	EPS next Q	-0.96	Inst Own	101.94%	Short Float / Ratio	26.16% / 6.42	Perf Quarter	-29.22%
Sales	145.88M	P/S	1.08	EPS this Y	39.26%	Inst Trans	-1.79%	Short Interest	12.31M	Perf Half Y	-74.98%
Book/sh	6.05	P/B	0.51	EPS next Y	47.55%	ROA	-27.25%	Target Price	8.20	Perf Year	-78.47%
Cash/sh	4.95	P/C	0.63	EPS next 5Y	-	ROE	-58.41%	52W Range	1.53 - 15.25	Perf YTD	-66.92%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-33.17%	52W High	-79.67%	Beta	1.14
Dividend %	-	Quick Ratio	4.08	Sales past 5Y	107.77%	Gross Margin	73.49%	52W Low	101.95%	ATR	0.30
Employees	425	Current Ratio	4.08	Sales Q/Q	-10.25%	Oper. Margin	-126.12%	RSI (14)	67.36	Volatility	15.20% 14.00%
Optionable	Yes	Debt/Eq	0.85	EPS Q/Q	20.46%	Profit Margin	-126.06%	Rel Volume	3.34	Prev Close	2.65
Shortable	Yes	LT Debt/Eq	0.81	Earnings	Nov 14 BMO	Payout	-	Avg Volume	1.92M	Price	3.10
Recom	2.14	SMA20	51.31%	SMA50	6.39%	SMA200	-58.54%	Volume	6,411,655	Change	16.98%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-30-23	Downgrade	Leerink Partners	Outperform → Market Perform	$6
Oct-12-23	Initiated	Citigroup	Buy	$13
Sep-13-23	Downgrade	Goldman	Buy → Neutral	$5
Sep-12-23	Downgrade	Guggenheim	Buy → Neutral
Jul-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$25 → $13
Oct-31-22	Initiated	Guggenheim	Buy	$30
May-02-22	Initiated	Goldman	Buy	$26
Feb-10-22	Initiated	SVB Leerink	Outperform	$38
Jan-06-22	Initiated	Cowen	Outperform
Nov-09-21	Initiated	Canaccord Genuity	Buy	$42
Nov-08-21	Initiated	Wedbush	Outperform
Nov-08-21	Initiated	Morgan Stanley	Overweight

Show Previous Ratings

Dec-06-23 02:00PM	2seventy bio Reiterates Commitment to Maximizing Shareholder Value (Business Wire) +9.30%
Nov-20-23 12:02PM	Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug (Investopedia) -18.31%
06:59AM	Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma (Business Wire)
Nov-14-23 07:00AM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-10-23 07:00AM	2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023 (Business Wire)
07:00AM	Loading…
Sep-12-23 07:00AM	2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway (Business Wire) -5.02%
06:55AM	2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies (Business Wire)
Sep-06-23 07:00AM	2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-24-23 09:00PM	CFO Baird William D III Sells 7,031 Shares of 2seventy bio Inc (TSVT) (GuruFocus.com)
Aug-14-23 07:00AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire)
Aug-08-23 07:00AM	2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023 (Business Wire)
Aug-01-23 04:15PM	2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference (Business Wire) -8.56%
Jun-14-23 07:00AM	2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia (Business Wire) -8.98%
Jun-07-23 07:00AM	2seventy bio to Participate in Upcoming Investor Conference (Business Wire)
May-19-23 06:00AM	2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (Business Wire)
07:17AM	Loading…
May-17-23 07:17AM	2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio (Business Wire)
May-11-23 12:37PM	2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 (Business Wire)
May-03-23 04:05PM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire)
May-02-23 04:37PM	2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting (Business Wire)
10:00AM	Billionaire Ken Griffin Doubles Down on These 2 Strong Buy Stocks Heres Why You Might Want to Follow in His Footsteps (TipRanks)
May-01-23 07:00AM	2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program (Business Wire) +8.31%
Apr-28-23 08:30AM	2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire) +5.78%
Apr-17-23 06:59AM	Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma (Business Wire)
Mar-16-23 04:05PM	2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress (Business Wire)
Mar-08-23 08:30AM	2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors (Business Wire)
Mar-03-23 07:00AM	2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference (Business Wire)
Mar-01-23 09:00AM	Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer (PR Newswire) -18.38%
Feb-28-23 09:00PM	2seventy bio Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
04:01PM	2seventy bio Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-10-23 11:13AM	Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study (Business Wire)
07:30AM	Loading…
Feb-01-23 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Jan-18-23 11:35AM	Medigene Receives $3 Million Milestone Payment from 2seventy bio (GlobeNewswire)
Jan-09-23 08:00AM	2seventy bio Provides Company Outlook for 2023 (Business Wire)
Jan-06-23 09:11AM	2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors (Business Wire)
Nov-07-22 04:05PM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-03-22 09:06AM	2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-27-22 07:00AM	2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies (Business Wire)
Sep-07-22 07:00AM	2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients (Business Wire) +5.76%
Aug-31-22 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-22 06:23AM	2seventy bio, Inc. (NASDAQ:TSVT) Analysts Just Slashed This Year's Revenue Estimates By 12% (Simply Wall St.)
Aug-10-22 06:50AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire)
06:45AM	Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma (Business Wire)
Aug-04-22 07:02AM	Will 2seventy bio (NASDAQ:TSVT) Spend Its Cash Wisely? (Simply Wall St.)
Aug-03-22 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-04-22 03:30PM	A 2seventy bio, Inc. (NASDAQ:TSVT) insider increased their holdings by 251% last year (Simply Wall St.)
Jun-06-22 07:30AM	2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference (Business Wire)
May-12-22 04:05PM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire)
May-04-22 09:10PM	Goldman Sachs Sees These 2 Strong Buy Stocks Skyrocketing Over 70% (TipRanks) +5.65%
Apr-08-22 04:15PM	2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting (Business Wire)
Apr-07-22 07:30AM	2seventy bio to Participate in CG Horizons in Oncology Virtual Conference (Business Wire)
Mar-22-22 07:00AM	2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress (Business Wire) +5.28%
Mar-16-22 08:41AM	2seventy bio Secures $170 Million in Private Placement Equity Financing (Business Wire) +14.59%
Feb-14-22 07:30AM	2seventy bio Announces Key Management Appointments (Business Wire)
07:00AM	2seventy bio to Participate in Upcoming Healthcare Conferences (Business Wire)
Feb-11-22 09:58AM	Do Institutions Own 2seventy bio, Inc. (NASDAQ:TSVT) Shares? (Simply Wall St.) -5.84%
Feb-03-22 01:38PM	Virginia Retirement Systems Et Al Buys Wolfspeed Inc, Orion Office REIT Inc, Kyndryl Holdings ... (GuruFocus.com)
Jan-26-22 08:00AM	Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer (GlobeNewswire) -9.53%
Jan-11-22 07:00AM	2seventy bio Shares Key Milestones and Business Updates for 2022 (Business Wire)
Jan-06-22 07:00AM	2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach (Business Wire) +10.22%
Dec-13-21 06:15PM	2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting (Business Wire) +8.26%
Dec-01-21 07:00AM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-15-21 10:43AM	Morgan Stanley: These 3 Strong Buy Stocks Could Surge at Least 60% (TipRanks)
Nov-10-21 04:30PM	2seventy bio to Present at the 5th Annual Cowen IO Next Summit (Business Wire) -5.08%

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leschly Nick	President and CEO	Aug 22	Sale	5.49	9,312	51,090	1,159,342	Aug 24 05:04 PM
Baird William D III	Chief Financial Officer	Aug 22	Sale	5.49	7,031	38,576	196,366	Aug 24 05:04 PM
Gregory Philip D	Chief Scientific Officer	Aug 22	Sale	5.49	6,159	33,791	257,250	Aug 24 05:04 PM
Kynam Capital Management, LP	10% Owner	Aug 10	Buy	5.92	515,414	3,049,287	5,953,825	Aug 14 08:51 PM
Kynam Global Healthcare Master	10% Owner	Aug 10	Buy	5.92	515,414	3,049,287	5,953,825	Aug 16 07:11 PM
Kynam Global Healthcare Master	10% Owner	Aug 10	Buy	5.96	86,414	515,027	5,142,111	Aug 16 07:11 PM
Kynam Capital Management, LP	10% Owner	Aug 10	Buy	5.96	86,414	515,027	5,142,111	Aug 14 08:51 PM
Leschly Nick	President and CEO	Aug 03	Sale	6.13	9,060	55,499	1,168,654	Aug 07 04:07 PM
Baird William D III	Chief Financial Officer	Aug 03	Sale	6.13	6,906	42,304	203,397	Aug 07 04:06 PM
Gregory Philip D	Chief Scientific Officer	Aug 03	Sale	6.13	3,966	24,295	263,409	Aug 07 04:06 PM
Baird William D III	Chief Financial Officer	Feb 13	Sale	12.86	637	8,192	210,303	Feb 15 05:56 PM
Heffron Nicola	Chief Operating Officer	Feb 07	Sale	14.70	60	882	89,182	Feb 09 04:32 PM
Leschly Nick	President and CEO	Jan 12	Sale	10.46	6,587	68,889	536,419	Jan 17 04:30 PM
Leschly Nick	President and CEO	Jan 11	Sale	10.63	2,026	21,533	534,393	Jan 18 05:18 PM
Baird William D III	Chief Financial Officer	Jan 11	Sale	10.63	1,077	11,446	78,797	Jan 18 05:18 PM
Gregory Philip D	Chief Scientific Officer	Jan 11	Sale	10.63	1,076	11,436	99,518	Jan 18 05:18 PM
Heffron Nicola	Chief Operating Officer	Jan 11	Sale	10.63	128	1,360	89,242	Jan 18 05:18 PM
Gregory Philip D	Chief Scientific Officer	Jan 09	Sale	10.33	3,794	39,210	100,594	Jan 11 04:23 PM
Baird William D III	Chief Financial Officer	Jan 09	Sale	10.33	3,222	33,298	79,874	Jan 11 04:23 PM
Leschly Nick	President and CEO	Jan 09	Sale	10.33	2,979	30,787	543,006	Jan 11 04:23 PM
Heffron Nicola	Chief Operating Officer	Jan 09	Sale	10.33	584	6,035	89,370	Jan 11 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TSVT

2seventy bio Inc

Upgrade your FINVIZ experience